Proteasome inhibitors related thrombotic microangiopathy: a systematic and comprehensive review
Abstract Proteasome inhibitors (PIs) are crucial in treating multiple myeloma but carry a risk of thrombotic microangiopathy (TMA), especially with carfilzomib use. This systematic review includes 44 studies with 115 cases of PI-induced TMA, where carfilzomib was implicated in 101 cases. Treatment a...
Saved in:
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2024-11-01
|
Series: | Blood Cancer Journal |
Online Access: | https://doi.org/10.1038/s41408-024-01182-9 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|